Prognostic and predictive drug-induced gene signatures for colorectal cancer patients personalized based on p53 status and treatment with FOLFOX, 5 FU, oxaliplatin, or irinotecan


Lindsey Carlsen1, Andrew Elliott2, Marzia Capelletti3, Micheal Hall4, Philip A. Philip5, Heinz-Josef Lenz6, Howard Safran7, Khaldoun Almhanna8, Rimini Breakstone8, Alexander G. Raufi1,8, Emil Lou10, John L. Marshall11, W. Michael Korn12, Wafik S. El-Deiry1,7. Fox Chase Cancer Center, Philadelphia, PA4, Wayne State University, Detroit, MI5, USC Norris Comprehensive Cancer Center, Los Angeles, CA6, The Rhode Island Hospital, Providence, RI7, Lifespan Cancer Institute, Providence, RI8, University of Minnesota, Minneapolis, MN10, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC11, University of California, San Francisco, CA12


Tumor expression of genes related to extent of drug exposure can predict outcomes after chemotherapy treatment.

•High EGR1 and FOS mRNA independently predict response to FOLFOX in patients with wild-type p53 tumors.

•Low CCNB1 mRNA correlates with good prognosis of CRC patients with tumors harboring TP53LOF mutations.

•Gene signatures may demonstrate enhanced predictive ability as compared to individual transcript effects.

•MSI status impacts the predictive of BTG2. 

Download Publication